<SEC-DOCUMENT>0001144204-15-053431.txt : 20150902
<SEC-HEADER>0001144204-15-053431.hdr.sgml : 20150902
<ACCEPTANCE-DATETIME>20150902155752
ACCESSION NUMBER:		0001144204-15-053431
CONFORMED SUBMISSION TYPE:	S-3/A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20150902
DATE AS OF CHANGE:		20150902

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cellectar Biosciences, Inc.
		CENTRAL INDEX KEY:			0001279704
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043321804
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-201429
		FILM NUMBER:		151089583

	BUSINESS ADDRESS:	
		STREET 1:		3301 AGRICULTURE DRIVE
		CITY:			MADISON
		STATE:			WI
		ZIP:			53716
		BUSINESS PHONE:		617-244-1616

	MAIL ADDRESS:	
		STREET 1:		3301 AGRICULTURE DRIVE
		CITY:			MADISON
		STATE:			WI
		ZIP:			53716

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVELOS THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20050617

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COMMON HORIZONS INC
		DATE OF NAME CHANGE:	20040211
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3/A
<SEQUENCE>1
<FILENAME>v419548_s3a.htm
<DESCRIPTION>FORM S-3/A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B> As filed with the Securities and
Exchange Commission on September 2, 2015 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B> Registration Statement No. 333-201429 </B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B> AMENDMENT No 1 to </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CELLECTAR BIOSCIENCES, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Exact name of registrant as specified
in its charter)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 51%; text-align: center; font-size: 10pt"><b>Delaware</b></td>
    <td style="width: 49%; text-align: center; font-size: 10pt"><font style="font-size: 10pt"><b>04-3321804</b></font></td></tr>
<tr style="vertical-align: top">
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(State or other jurisdiction of</i></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>incorporation or organization)</i></P></td>
    <td>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>(I.R.S. Employer</i></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>Identification Number)</i></P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 100%; text-align: center; font-size: 10pt"><b>3301 Agriculture Drive</b></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center; font-size: 10pt"><b>Madison, WI&nbsp;&nbsp;53716</b></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(608) 441-8120</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Address, including zip code, and telephone
number,</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>including area code, of registrant&rsquo;s
principal executive offices)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B> James Caruso </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>President and Chief Executive Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>3301 Agriculture Drive</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Madison, WI 53716</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name and address of agent for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(608) 441-8120 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Telephone number, including area code,
of agent for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Copy to:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Paul Bork, Esq.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Foley Hoag <FONT STYLE="font-variant: small-caps">LLP</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>155 Seaport Boulevard</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Boston, Massachusetts 02210</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Telephone: (617)&nbsp;832-1000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Telecopy: (617)&nbsp;832-7000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Approximate date of commencement
of proposed sale to the public:</I></B> From time to time after this registration statement becomes effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If the only securities being registered
on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If any of the securities being registered
on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than
securities offered only in connection with dividend or interest reinvestment plans, check the following box. <FONT STYLE="font-family: Wingdings">&thorn;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If this Form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings">&uml;</FONT>
___________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If this Form is a post-effective amendment
filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings">&uml;</FONT>
___________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If this Form is a registration statement
pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission
pursuant to Rule 462(e) under the Securities Act, check the following box. <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If this Form is a post-effective amendment
to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes
of securities pursuant to Rule 413(b) under the Securities Act, check the following box. <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule 12b-2
of the Exchange Act. (Check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td nowrap style="width: 24%; text-align: center; font-size: 10pt">Large accelerated filer&nbsp;&nbsp;<font style="font-family: Wingdings">&uml;</font></td>
    <td nowrap style="width: 19%; text-align: center; font-size: 10pt">Accelerated filer&nbsp;<font style="font-family: Wingdings">&uml;</font></td>
    <td nowrap style="width: 30%; text-align: center; font-size: 10pt">Non-accelerated filer&nbsp;<font style="font-family: Wingdings">&uml;</font></td>
    <td nowrap style="width: 27%; text-align: center; font-size: 10pt">Smaller reporting company&nbsp;<font style="font-family: Wingdings">&thorn;</font></td></tr>
<tr style="vertical-align: top">
    <td nowrap style="text-align: center; font-size: 10pt">&nbsp;</td>
    <td nowrap style="text-align: center; font-size: 10pt">&nbsp;</td>
    <td nowrap style="text-align: center; font-size: 10pt">(Do not check if a <br>
smaller reporting company)</td>
    <td nowrap style="text-align: center; font-size: 10pt">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The registrant hereby amends this registration statement on
such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically
states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act,
or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant
to said Section 8(a), may determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt; text-align: left; font-size: 10pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="color: #DE1A1E; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B> The information in this prospectus is
not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and
Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy
these securities in any state where the offer or sale is not permitted. </B></P>

<P STYLE="color: #DE1A1E; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0"><B>Prospectus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Subject to completion, dated</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B> September 2, 2015 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>$5,000,000</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tlogo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Warrants</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus provides you with a general
description of securities that we may offer and sell from time to time. Each time we sell securities we will provide a prospectus
supplement that will contain specific information about the terms of that sale and may add to or update the information in this
prospectus. You should read this prospectus and any applicable prospectus supplement carefully before you invest in our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The securities
may be offered directly by us</FONT> <FONT STYLE="font-size: 10pt">through agents designated from time to time by us or to or through
underwriters or dealers. If any agents, underwriters or dealers are involved in the sale of any of the securities, their names
and any applicable purchase price, fee, commission or discount arrangement between or among them will be set forth, or will be
calculable from the information set forth, in the applicable prospectus supplement. See the sections entitled &ldquo;About This
Prospectus&rdquo; and &ldquo;How We Plan to Offer and Sell the Securities&rdquo; for more information. No securities may be sold
by us without delivery of this prospectus and the applicable prospectus supplement describing the method and terms of the offering
of such securities. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our common stock is listed on the NASDAQ
Capital Market under the symbol &ldquo;CLRB.&rdquo; On August 28, 2015, the last reported sale price of our common stock on the
NASDAQ Capital Market was $3.07 per share. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of August 28, 2015, the aggregate
market value of our outstanding common stock held by non-affiliates was approximately $13.7 million, which was calculated based
on 4,477,364 shares of outstanding common stock held by non-affiliates and on a price per share of $3.07. Pursuant to General
Instruction I.B.6 of Form S-3, in no event will we sell the shelf securities in a public primary offering with a value exceeding
more than one-third of the aggregate market value of our common stock held by non-affiliates in any 12-month period so long as
the aggregate market value of our outstanding common stock held by non-affiliates remains below $75 million. During the 12 calendar
months prior to and including the date of this prospectus, we have not offered or sold any securities pursuant to General Instruction
I.B.6 of Form S-3. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Investing in our securities involves
various risks. In our filings with the Securities and Exchange Commission, which are incorporated by reference in this prospectus,
we identify and discuss risk factors that you should consider before investing in our securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities, or determined if this prospectus is truthful
or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus&nbsp;is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2015.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt; text-align: left; font-size: 10pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Table of Contents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 94%; text-align: right; padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="width: 6%; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Page </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>RISK FACTORS</B></FONT></A> </TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"> 5 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>SPECIAL NOTE REGARDING FORWARD-LOOKING
    STATEMENTS</B></FONT></A> </TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"> 5 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>HOW WE INTEND TO USE THE PROCEEDS</B></FONT></A> </TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"> 5 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>DESCRIPTION OF COMMON STOCK</B></FONT></A> </TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"> 6 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>DESCRIPTION OF WARRANTS</B></FONT></A> </TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"> 9 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>DESCRIPTION OF UNITS</B></FONT></A> </TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"> 10 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>HOW WE PLAN TO OFFER AND SELL THE SECURITIES</B></FONT></A> </TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"> 11 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>INCORPORATION OF CERTAIN INFORMATION BY
    REFERENCE</B></FONT></A> </TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"> 13 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>WHERE YOU CAN FIND MORE INFORMATION</B></FONT></A> </TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"> 14 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD> <A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>EXPERTS</B></FONT></A> </TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"> 14 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD> <A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>LEGAL MATTERS</B></FONT></A> </TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"> 14 </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This document is called a &ldquo;prospectus,&rdquo;
and it provides you with a general description of the securities we may offer. Each time we sell securities, we will provide a
prospectus supplement containing specific information about the terms of the securities being offered. That prospectus supplement
may include a discussion of any risk factors or other special considerations that apply to those securities. The prospectus supplement
may also add to, update or change the information in this prospectus. If there is any inconsistency between the information in
this prospectus and in a prospectus supplement, you should rely on the information in that prospectus supplement. You should read
both this prospectus and any prospectus supplement together with additional information described under the heading &ldquo;Where
You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have filed a registration statement with
the Securities and Exchange Commission, or the SEC, using a shelf registration process. Under this shelf registration process,
we may offer and sell any combination of the securities described in this prospectus in one or more offerings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our SEC registration statement containing
this prospectus, including exhibits, provides additional information about us and the securities offered under this prospectus.
The registration statement can be read at the SEC&rsquo;s web site or at the SEC&rsquo;s offices. The SEC&rsquo;s web site and
street address are provided under the heading &ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">When acquiring securities, you should rely
only on the information provided in this prospectus and in the related prospectus supplement, including any information incorporated
by reference. No one is authorized to provide you with information different from that which is contained, or deemed to be contained,
in the prospectus and related prospectus supplement. We are not offering the securities in any state where the offer is prohibited.
You should not assume that the information in this prospectus, any prospectus supplement or any document incorporated by reference
is truthful or complete as of any date other than the date indicated on the cover page of the relevant document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless otherwise stated or unless the context
otherwise requires, all references to &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;our company&rdquo; or &ldquo;the
Company&rdquo; in this prospectus refer collectively to Cellectar Biosciences, Inc., a Delaware corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This section contains a general summary
of the information contained in this prospectus. It may not include all of the information that is important to you. You should
read the entire prospectus, any accompanying prospectus supplement and the documents incorporated by reference before making an
investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Cellectar Biosciences, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The Company is a biopharmaceutical company developing phospholipid
ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Our PDC platform is based on our cancer-targeting
and delivery technology which provides selective delivery of a diverse range of oncologic payloads to cancer cells, including
cancer stem cells. By linking various payloads to our proprietary phospholipid ether cancer-targeting vehicle, we believe we can
create PDCs with the potential to provide highly targeted delivery of chemotherapeutic and radiotherapeutic payloads to a broad
range of cancers. As a result, our PDC platform has the potential to improve the therapeutic index of payloads by minimizing delivery
to healthy cells while enhancing delivery to a broad range of cancers. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> The Company currently has several proprietary product candidates
in development, including: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> I-131-CLR1404
                                         is a small-molecule, broad-spectrum, cancer-targeting radiotherapeutic PDC that is designed
                                         to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells
                                         and cancer stem cells. I-131-CLR1404 is our lead PDC therapeutic product candidate and
                                         is currently being evaluated in a phase I study in relapse/refractory multiple myeloma.
                                         This indication was selected for clinical and business related reasons including multiple
                                         myeloma&rsquo;s highly radiosensitive nature, clear unmet medical need in the relapse/refractory
                                         setting and orphan drug designation. Multiple myeloma is an incurable cancer of plasma
                                         cells. The Investigational New Drug (IND) application was accepted by the U.S. Food and
                                         Drug Administration (FDA) in March 2014. In December 2014, the FDA granted orphan drug
                                         designation for I-131-CLR1404 for the treatment of multiple myeloma.<FONT STYLE="font: 10pt Times New Roman, Times, Serif">
                                         </FONT>We initiated the phase I study in April of this year and anticipate evaluating
                                         our first cohort and initiating the second cohort in Q1 2016. The primary goal of the
                                         phase I study is to identify a phase II dose, and possibly obtain an early read on low
                                         dose efficacy. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> CLR1601-PTX
                                         and CLR1800-GEM are small-molecule, broad-spectrum, cancer-targeting therapeutic PDCs
                                         designed to deliver their respective chemotherapeutic payloads, paclitaxel and gemcitabine,
                                         selectively and directly to cancer cells and cancer stem cells. Both PDCs are pre-clinical,
                                         and we are developing <I>in vivo</I> and <I>in vitro</I> data to demonstrate stability
                                         and efficacy. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> I-124-CLR1404
                                         is a small-molecule, broad-spectrum, cancer-targeting positron emission tomography (PET)
                                         imaging PDC that we believe has the potential to be the first of its kind for the selective
                                         detection of tumors and metastases in a broad range of cancers. I-124-CLR1404 has been
                                         used for PET/CT imaging in a broad array of tumor types via both Company and investigator-sponsored
                                         clinical trials, and we are in the process of evaluating the data from those studies.
                                         In April 2014, the FDA granted I-124-CLR1404 orphan status as a diagnostic for the management
                                         of glioma. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> CLR1502 is
                                         a small-molecule, broad-spectrum cancer-targeting, NIR-fluorophore optical imaging PDC
                                         for intraoperative tumor and tumor margin illumination. This past June, after review
                                         of the Company's IND application, the FDA determined that CLR1502 will be evaluated as
                                         a combination product and assigned to the Center for Devices and Radiological Health
                                         (CDRH). As a result of this classification, the FDA has advised Cellectar that it will
                                         need to submit a new investigational application for the combination product prior to
                                         initiating its phase I study in breast cancer surgery. As a result, Cellectar is identifying
                                         the optimal clinical development pathway. Based on the Company&rsquo;s assessment, the
                                         product will be similarly treated post marketing approval regardless of regulatory pathway. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> We believe our PDC platform has potential
to provide targeted delivery of oncologic payloads, as exemplified by the product candidates listed above, that my result in improvements
upon current standard of care (SOC) for the treatment, diagnosis and imaging of a broad range of human cancers. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> &nbsp; </P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our headquarters and manufacturing operation
is located at 3301 Agriculture Drive, Madison, Wisconsin 53716. We maintain a website at www.cellectar.com. The information included
or referred to on, or accessible through, our website does not constitute part of, and is not incorporated by reference into, this
prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The Securities That May Be Offered </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The descriptions of the securities contained
in this prospectus, together with an applicable prospectus supplement, summarize all the material terms and provisions of the various
types of securities that may be offered under this prospectus and any applicable prospectus supplement. We will describe in the
applicable prospectus supplement relating to any securities the particular terms of the securities offered by that prospectus supplement.
If we so indicate in the applicable prospectus supplement, the terms of the securities may differ from the terms we have summarized
below. We may also include in the prospectus supplement information, where applicable, about material United States federal income
tax considerations relating to the securities, and the securities exchange or market, if any, on which the securities will be listed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may sell from time to time, in one or
more offerings the following securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>common stock;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>warrants to purchase common stock; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>units consisting of a combination of the foregoing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The aggregate offering price of all securities
that we may sell under this prospectus and applicable prospectus supplements will not exceed $5,000,000. In no event, however,
will we sell securities in a primary offering pursuant to General Instruction I.B.6 of Form S-3 with a value exceeding more than
one-third of our public float in any 12-month period so long as our public float remains below $75 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Risks Affecting Us </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our business is subject to a number of risks,
which are highlighted in the section entitled &ldquo;Risk Factors&rdquo; immediately following this summary and in the prospectus
supplement and the documents incorporated by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Prior to making an investment decision
with respect to the securities that we may offer, prospective investors should carefully consider, in light of their particular
investment objectives and financial circumstances, the specific factors set forth under the caption &ldquo;Risk Factors&rdquo;
in the applicable prospectus supplement pertaining thereto and in our most recent annual report on Form 10-K/A and any subsequent
quarterly reports on Form 10-Q filed with the SEC, as well as any amendments thereto reflected in subsequent filings with the
SEC, and in any of our other filings with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act
of 1934, as amended, or the Exchange Act, incorporated by reference into this prospectus and the applicable prospectus supplement.
For more information, see &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation of Certain Information by
Reference.&rdquo; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus and the documents incorporated
by reference in this prospectus, contain forward-looking statements. You should carefully consider the various risk factors described
above that are incorporated by reference into this prospectus from our SEC filings, which risk factors may cause our actual results
to differ materially from those indicated by such forward-looking statements. You should not place undue reliance on our forward-looking
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_003"></A>HOW WE INTEND TO USE THE PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless stated differently in a prospectus
supplement, we will use the net proceeds from the sale of the securities that we may offer with this prospectus and any accompanying
prospectus supplement to fund research and development activities for our current product candidates and for general corporate
purposes. General corporate purposes may include the payment of general and administrative expenses, capital expenditures, working
capital, prosecution and maintenance of our intellectual property and any other purposes that we may specify in any prospectus
supplement. We may invest the net proceeds temporarily until we use them for their stated purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_004"></A>DESCRIPTION OF COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>The following summary description of
our common stock is based on the provisions of our Second Amended and Restated Certificate of Incorporation, as amended, which
we refer to as our certificate of incorporation or charter, our by-laws, and the applicable provisions of the Delaware General
Corporation Law, which we refer to as the DGCL. This description may not contain all of the information that is important to you
and is subject to, and is qualified in its entirety by reference to our certificate of incorporation, our by-laws and the applicable
provisions of the DGCL. For information on how to obtain copies of our certificate of incorporation and by-laws, see &ldquo;Where
You Can Find More Information.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Authorized and Outstanding Capital Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our authorized capital stock consists
of 40,000,000 shares of common stock, $0.00001 par value per share and 7,000 shares of preferred stock, $0.00001 par value per
share. Our certificate of incorporation authorizes us to issue shares of our preferred stock from time to time in one or more
series without stockholder approval, each such series to have rights and preferences, including voting rights, dividend rights,
conversion rights, redemption privileges and liquidation preferences as our board of directors may determine. The rights of the
holders of common stock will be subject to, and may be adversely affected by, the rights of holders of any preferred stock that
we may issue in the future. The issuance of preferred stock, while providing desirable flexibility in connection with possible
acquisitions and other corporate purposes, could have the effect of making it more difficult for others to acquire, or of discouraging
others from attempting to acquire, a majority of our outstanding voting stock. We currently have no plans to issue any shares
of preferred stock. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> As of August 28, 2015, we had 7,564,133
shares of common stock outstanding and no shares of preferred stock outstanding. All outstanding shares of our common stock are
duly authorized, validly issued, fully paid and nonassessable. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Reverse Stock Split and Recapitalization</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> At our annual meeting of stockholders
held on May 22, 2014, our stockholders approved an amendment to our certificate of incorporation to effect a reverse split of
our common stock at a ratio between 1:10 to 1:20 in order to satisfy requirements for the listing of our common stock on the NASDAQ
Capital Market. In addition, the proposal approved by the stockholders provided that if the reverse split was effected, the number
of shares of Common Stock that the Corporation is authorized to issue would be reduced from 150,000,000 to the greater of (A)
20,000,000 and (B) a number of shares equal to three (3) times the sum of (i) the number of all shares of our common stock outstanding
and (ii) the number of shares of common stock issuable upon exercise or conversion of all outstanding options, warrants and convertible
debt. Our stockholders further authorized the board of directors to determine the ratio at which the reverse split would be effected
and the corresponding reduction in authorized shares of common stock by filing an appropriate amendment to our certificate of
incorporation. Our board of directors authorized the ratio of the Reverse Split and corresponding reduction in authorized shares
on June 6, 2014 and effective at the close of business on June 13, 2014, we amended our Second Amended and Restated Certificate
of Incorporation to effect the Listing Reverse Split and reduce the number of authorized shares of our common stock to 20,000,000
from 150,000,000. All share and per share numbers included in this prospectus give effect to the Listing Reverse Split. At our
stockholders&rsquo; meeting, held on June 9, 2015, our stockholders approved a further amendment to our certificate of incorporation
to increase the authorized number of shares of common stock from 20,000,000 to 40,000,000. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Voting.</I> Holders of our common stock
are entitled to one vote per share held of record on all matters to be voted upon by our stockholders. Our common stock does not
have cumulative voting rights. Persons who hold a majority of the outstanding common stock entitled to vote on the election of
directors can elect all of the directors who are eligible for election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Dividends. </I>Subject to preferences
that may be applicable to the holders of any outstanding shares of our preferred stock, the holders of our common stock are entitled
to receive such lawful dividends as may be declared by our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Liquidation and Dissolution. </I>In the
event of our liquidation, dissolution or winding up, and subject to the rights of the holders of any outstanding shares of our
preferred stock, the holders of shares of our common stock will be entitled to receive pro rata all of our remaining assets available
for distribution to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Other rights and Restrictions. </I>Our
charter prohibits us from granting preemptive rights to any of our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Anti-Takeover Effect of Certain Charter and By-Law Provisions
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Provisions of our charter and our by-laws
could make it more difficult to acquire us by means of a merger, tender offer, proxy contest, open market purchases, removal of
incumbent directors and otherwise. These provisions, which are summarized below, are expected to discourage types of coercive takeover
practices and inadequate takeover bids and to encourage persons seeking to acquire control of us to first negotiate with us. We
believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or
unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging takeover or acquisition proposals
because negotiation of these proposals could result in an improvement of their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Authorized but Unissued Stock</I>. We
have shares of common stock and preferred stock available for future issuance, in some cases, without stockholder approval. We
may issue these additional shares for a variety of corporate purposes, including public offerings to raise additional capital,
corporate acquisitions, stock dividends on our capital stock or equity compensation plans. The existence of unissued and unreserved
common stock and preferred stock may enable our board of directors to issue shares to persons friendly to current management or
to issue preferred stock with terms that could render more difficult or discourage a third-party attempt to obtain control of us,
thereby protecting the continuity of our management. In addition, if we issue preferred stock, the issuance could adversely affect
the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon
liquidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Amendments to By-laws</I>. Our certificate
of incorporation and by-laws authorize the Board to amend, repeal, alter or rescind the by-laws at any time without stockholder
approval. Allowing the Board to amend our by-laws without stockholder approval enhances Board control over our by-laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Classification of Board; Removal of Directors;
Vacancies.</I> Our certificate of incorporation provide for the division of the Board into three classes as nearly equal in size
as possible with staggered three-year terms; that directors may be removed only for cause by the affirmative vote of the holders
of two-thirds of our shares of capital stock entitled to vote; and that any vacancy on the Board, however occurring, including
a vacancy resulting from an enlargement of the board, may be filled only by the vote of a majority of the directors then in office.
The limitations on the removal of directors and the filling of vacancies could have the effect of making it more difficult for
a third party to acquire, or of discouraging a third party from acquiring, control of us. Our certificate of incorporation requires
the affirmative vote of the holders of at least 75% of our shares of capital stock issued and outstanding and entitled to vote
to amend or repeal any of these provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Notice Periods for Stockholder Meetings</I>.
Our by-laws provide that for business to be brought by a stockholder before an annual meeting of stockholders, the stockholder
must give written notice to the corporation not less than 90 nor more than 120 days prior to the one year anniversary of the date
of the annual meeting of stockholders of the previous year; provided, however, that in the event that the annual meeting of stockholders
is called for a date that is not within 30 days before or after such anniversary date, notice by the stockholder must be received
not later than the close of business on the tenth day following the day on which the corporation's notice of the date of the meeting
is first given or made to the stockholders or disclosed to the general public, whichever occurs first.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Stockholder Action; Special Meetings</I>.
Our certificate of incorporation provides that stockholder action may not be taken by written action in lieu of a meeting and provides
special meetings of the stockholders may only be called by our president or by our Board. These provisions could have the effect
of delaying until the next stockholders' meeting stockholder actions that are favored by the holders of a majority of our outstanding
voting securities. These provisions may also discourage another person or entity from making a tender offer for our common stock,
because that person or entity, even if it acquired a majority of our outstanding voting securities, would be able to take action
as a stockholder only at a duly called stockholders' meeting, and not by written consent. Our certificate of incorporation requires
the affirmative vote of the holders of at least 75% of our shares of capital stock issued and outstanding and entitled to vote
to amend or repeal the provisions relating to prohibition on action by written consent and the calling of a special meeting of
stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Nominations</I>. Our by-laws provide
that nominations for election of directors may be made only by (i) the Board or a committee appointed by the Board; or (ii) a stockholder
entitled to vote on director election, if the stockholder provides notice to the Secretary of the Corporation presented not less
than 90 days nor more than 120 days prior to the anniversary of the last annual meeting (subject to the limited exceptions set
forth in the bylaws). These provisions may deter takeovers by requiring that any stockholder wishing to conduct a proxy contest
have its position solidified well in advance of the meeting at which directors are to be elected and by providing the incumbent
Board with sufficient notice to allow them to put an election strategy in place.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NASDAQ Capital Market Listing </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Our common stock is listed for trading
and quotation on the NASDAQ Capital Market under the trading symbol &ldquo;CLRB.&rdquo; Certain warrants to purchase shares of
our common stock expiring on August 20, 2019 are also listed on the NASDAQ Capital market under
the trading symbol &ldquo;CLRBW.&rdquo; On August 14, 2015, the Company received notice from Nasdaq which indicated that under
Nasdaq Listing Rule 5550(b)(1), the Company is required to maintain a minimum of $2,500,000 in stockholders&rsquo; equity for
continued listing. In the Company&rsquo;s Form 10-Q for the period ended June 30, 2015, we reported stockholders&rsquo; equity
was $2,373,371. The Company has until September 28, 2015 to submit a plan to Nasdaq to regain compliance, which it intends to
provide. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The transfer agent and registrar for our
common stock is American Stock Transfer and Trust Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>DESCRIPTION OF WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following summary describes generally
the terms of warrants to purchase shares of our common stock that we may offer from time to time in one or more series. The specific
terms of a series of warrants will be described in the applicable prospectus supplement relating to that series of warrants. Each
series of warrants will be issued under a separate warrant agreement between us and a warrant agent specified in the related prospectus
supplement. The warrant agent will act solely as our agent in connection with the warrants of a series and will not assume any
obligation or relationship of agency or trust for or with holders or beneficial owners of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following description of the warrants
may not contain all of the information that is important to you and is subject to, and qualified in its entirety by reference to,
the underlying warrant agreement, which we will file with the SEC at or prior to the time of the sale of the warrants. You should
refer to, and read this summary together with, the<FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT>form of warrant
agreement and the applicable prospectus supplement for a full understanding of the specific terms of any warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The applicable prospectus supplement will
describe the terms of any warrants, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the title of the warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the aggregate number of the warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the price or prices at which the warrants will be issued and sold;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the number of shares of common stock purchasable upon exercise of the warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the price at which the common stock purchasable upon exercise of the warrants may be purchased;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the date on which the right to exercise the warrants shall commence and the date on which that right will expire;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether the warrants will be issued in registered form or bearer form;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if applicable, the minimum or maximum amount of the warrants which may be exercised at any one time;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if applicable, the date on and after which the warrants and the related underlying securities will be separately transferable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>information with respect to book-entry procedures, if any;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if applicable, a summary of the United States federal income tax considerations; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any other terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Prior to the exercise of their warrants,
holders of warrants will not have any of the rights of holders of the respective underlying securities purchasable upon exercise
of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>DESCRIPTION OF UNITS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following summary describes generally
the terms of the units that we may offer under this prospectus. Each unit will be issued so that the holder of the unit is also
the holder of each security included in the unit. Thus, each unit will entitle the holder thereof to the rights and obligations
of a holder of each security included in such unit. The specific terms of a series of units will be described in the applicable
prospectus supplement relating to that series of units. Units will be issued pursuant to the terms of a unit agreement, which may
provide that the securities included in the unit may not be held or transferred separately at any time or at any time before a
specified date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following description of the units may
not contain all of the information that is important to you and is subject to, and qualified in its entirety by reference to, the
underlying unit agreement, which we will file with the SEC at or prior to the time of the sale of the units. You should refer to,
and read this summary together with, the unit agreement and the applicable prospectus supplement for a full understanding of the
specific terms of any series of units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The applicable prospectus supplement will
describe the terms of any units, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the designation and terms of the units and the securities comprising the units, including whether and under what circumstances
those securities may be held or transferred separately;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any provision for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the
units; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>whether the units will be issued in fully registered or global form.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007"></A>HOW WE PLAN TO OFFER AND SELL THE SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may sell the securities in any one or
more of the following ways:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>directly to investors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to investors through agents;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>to dealers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>through a special offering, an exchange distribution or a secondary distribution in accordance with applicable Nasdaq Capital
Market or other stock exchange rules;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>through underwriting syndicates led by one or more managing underwriters; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>through one or more underwriters acting alone.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any underwritten offering may be on a best
efforts or a firm commitment basis. We may also make direct sales through subscription rights distributed to our stockholders on
a pro rata basis, which may or may not be transferable. In any distribution of subscription rights to stockholders, if all of the
underlying securities are not subscribed for, we may then sell the unsubscribed securities directly to third parties or may engage
the services of one or more underwriters, dealers or agents, including standby underwriters, to sell the unsubscribed securities
to third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The distribution of the securities may be
effected from time to time in one or more transactions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at a fixed price or prices, which may be changed;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at market prices prevailing at the time of sale;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at prices related to such prevailing market prices; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>at negotiated prices.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any of the prices may represent a discount
from the prevailing market prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the sale of the securities, underwriters
or agents may receive compensation from us or from purchasers of the securities, for whom they may act as agents, in the form of
discounts, concessions or commissions. Underwriters may sell the securities to or through dealers, and such dealers may receive
compensation in the form of discounts, concessions or commissions from the underwriters and/or commissions from the purchasers
for whom they may act as agents. Underwriters, dealers and agents that participate in the distribution of the securities may be
deemed to be underwriters under the Securities Act of 1933, as amended, or the Securities Act, and any discounts or commissions
they receive from us and any profit on the resale of securities they realize may be deemed to be underwriting discounts and commissions
under the Securities Act. The applicable prospectus supplement will, where applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>identify any such underwriter or agent;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>describe any compensation in the form of discounts, concessions, commissions or otherwise received from us by each such underwriter
or agent and in the aggregate to all underwriters and agents;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>identify the amounts underwritten;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>identify the nature of the underwriter&rsquo;s obligation to take the securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>and any other material terms of the offering, including any over-allotment option.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Common stock sold by us pursuant to a prospectus
supplement will be listed on the Nasdaq Capital Market, subject to the Nasdaq Capital Market&rsquo;s approval of the listing of
the additional shares. We may elect to list other securities on an exchange, but we are not obligated to do so. It is possible
that one or more underwriters may make a market in a series of securities, but such underwriters will not be obligated to do so
and may discontinue any market making at any time without notice. Therefore, no assurance can be given as to the liquidity of,
or the trading market for, any series of securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Until the distribution of the securities
is completed, rules of the Securities and Exchange Commission may limit the ability of any underwriters and selling group members
to bid for and purchase the securities. As an exception to these rules, underwriters are permitted to engage in some transactions
that stabilize the price of the securities. Such transactions consist of bids or purchases for the purpose of pegging, fixing or
maintaining the price of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If any underwriters create a short position
in the securities in an offering in which they sell more securities than are set forth on the cover page of the applicable prospectus
supplement, the underwriters may reduce that short position by purchasing the securities in the open market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The lead underwriters may also impose a
penalty bid on other underwriters and selling group members participating in an offering. This means that if the lead underwriters
purchase securities in the open market to reduce the underwriters&rsquo; short position or to stabilize the price of the securities,
they may reclaim the amount of any selling concession from the underwriters and selling group members who sold those securities
as part of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In general, purchases of a security for
the purpose of stabilization or to reduce a short position could cause the price of the security to be higher than it might be
in the absence of such purchases. The imposition of a penalty bid might also have an effect on the price of a security to the extent
that it discourages resales of the security before the distribution is completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We do not make any representation or prediction
as to the direction or magnitude of any effect that the transactions described above might have on the price of the securities.
In addition, we do not make any representation that underwriters will engage in such transactions or that such transactions, once
commenced, will not be discontinued without notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under agreements into which we may enter,
underwriters, dealers and agents who participate in the distribution of the securities may be entitled to indemnification by us
against some liabilities, including liabilities under the Securities Act, or to contribution from us with respect to such liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Underwriters, dealers and agents may engage
in transactions with us, perform services for us or be our customers in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If indicated in the applicable prospectus
supplement, we will authorize underwriters or other persons acting as our agents to solicit offers by particular institutions to
purchase securities from us at the public offering price set forth in such prospectus supplement pursuant to delayed delivery contracts
providing for payment and delivery on the date or dates stated in such prospectus supplement. Each delayed delivery contract will
be for an amount no less than, and the aggregate principal amounts of securities sold under delayed delivery contracts shall be
not less nor more than, the respective amounts stated in the applicable prospectus supplement. Institutions with which such contracts,
when authorized, may be made include commercial and savings banks, insurance companies, pension funds, investment companies, educational
and charitable institutions and others, but will in all cases be subject to our approval. The obligations of any purchaser under
any such contract will be subject to the conditions that (a)&nbsp;the purchase of the securities shall not at the time of delivery
be prohibited under the laws of any jurisdiction in the United States to which the purchaser is subject, and (b)&nbsp;if the securities
are being sold to underwriters, we shall have sold to the underwriters the total principal amount of the securities less the principal
amount thereof covered by the contracts. The underwriters and such other agents will not have any responsibility in respect of
the validity or performance of such contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To comply with applicable state securities
laws, the securities offered by this prospectus will be sold, if necessary, in such jurisdictions only through registered or licensed
brokers or dealers. In addition, securities may not be sold in some states unless they have been registered or qualified for sale
in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_008"></A>INCORPORATION OF CERTAIN INFORMATION
BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Securities and Exchange Commission allows
us to incorporate by reference information into this prospectus. This means that we can disclose important information to you by
referring you to another document filed separately with the SEC. The information incorporated by reference is considered to be
a part of this prospectus, except for any information that is superseded by information that is included directly in this prospectus
or incorporated by reference subsequent to the date of this prospectus. We do not incorporate the contents of our website into
this prospectus. We incorporate by reference the filed documents listed below, except as superseded, supplemented or modified by
this prospectus, and any future filings we will make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act
until all of the shelf securities are sold:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> our Annual
                                         Report on Form 10-K/A for the fiscal year ended December 31, 2014 filed on May 20, 2015; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> our Quarterly
                                         Report on Form 10-Q for the quarter ended March 31, 2015 filed on May 20, 2015; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> our Quarterly
                                         Report on Form 10-Q for the quarter ended June 30, 2015 filed on August 12, 2015; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> our Current
                                         Report on Form 8-K for the event date of June 9, 2015 filed on June 11, 2015; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> our Current
                                         Report on Form 8-K for the event date of June 15, 2015 filed on June 16, 2015; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> our Current
                                         Report on Form 8-K for the event date of June 15, 2015 filed on June 19, 2015; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> our Current
                                         Report on Form 8-K for the event date of July 1, 2015 filed on July 8, 2015; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> our Current
                                         Report on Form 8-K for the event date of July 28, 2015 filed on July 31, 2015; </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"> &middot; </FONT></TD><TD> our Current
                                         Report on Form 8-K for the event date of August 14, 2015 filed on August 19, 2015; and </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the description of our securities contained in our Registration Statement on Form 8-A filed on August 14, 2014, including any
amendment or report filed for the purpose of updating such description.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, we incorporate by reference
all documents that we may file with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act on or after (1)
the date of the initial registration statement and prior to the effectiveness of the registration statement and (2) the date of
effectiveness of the registration statement until the date on which this registration statement has been withdrawn. These documents
will become a part of this prospectus from the date that the documents are filed with the SEC. These documents include periodic
reports, such as annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, excluding any information
filed or furnished pursuant to Item 2.02, Item 7.01 or Item 9.01 and excluding any information furnished pursuant to Item 8.01
of any current report on Form 8-K solely for purposes of satisfying the requirements of Regulation FD under the Exchange Act, unless
such Form 8-K expressly provides to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon oral or written request and at no cost
to the requester, we will provide to each person, including any beneficial owner, to whom a prospectus is delivered, a copy of
any or all of the information that has been incorporated by reference in this prospectus but not delivered with this prospectus.
You may request copies of these filings, at no cost, by writing to us at Cellectar Biosciences, Inc., 3301 Agriculture Drive, Madison,
WI 53716, Attention: Chief Financial Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus is part of a registration
statement on Form S-3 that we filed with the SEC under the Securities Act. This prospectus does not contain all of the information
contained in the registration statement. For further information about us and our securities, you should read the prospectus and
the exhibits filed with the registration statement, as well as all prospectus supplements.</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a reporting company and file annual,
quarterly and special reports, and other information with the Securities and Exchange Commission. Copies of the reports and other
information may be read and copied at the SEC&rsquo;s Public Reference Room at 100 F Street NE, Washington, D.C. 20549. You can
request copies of such documents by writing to the SEC and paying a fee for the copying cost. You may obtain information on the
operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains a web site at <I>http://www.sec.gov</I>
that contains reports, proxy and information statements and other information regarding registrants that file electronically with
the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_010"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The audited financial statements incorporated
by reference in this prospectus and elsewhere in the registration statement have been so incorporated by reference in reliance
upon the report of Grant Thornton LLP, independent registered public accountants, upon the authority of said firm as experts in
accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_011"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The legality of the securities offered hereby
will be passed upon for us by Foley Hoag <FONT STYLE="font-variant: small-caps">llp </FONT>of Boston, Massachusetts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Part II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 14. Other Expenses of Issuance and Distribution.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The expenses in connection with the issuance
and distribution of the securities being registered are set forth in the following table (all amounts other than the registration
fee are estimated):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 92%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 82%; text-align: left">Registration fee &mdash; Securities and Exchange Commission</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">581</TD><TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accountants&rsquo; fees and expenses</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; text-align: left">**</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Legal fees and expenses</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; text-align: left">**</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stock exchange listing fees</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; text-align: left">**</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Printing expenses</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; text-align: left">**</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Miscellaneous</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">**</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">TOTAL</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">581</TD><TD NOWRAP STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-left: 0.25in; margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">**</TD><TD>These fees and expenses cannot be estimated at this time because the amounts will be affected by the number of offerings and
the method of offering.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 15. Indemnification of Directors and Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;102 of the Delaware General
Corporation Law permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its
stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of
loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of
a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;145 of the Delaware General
Corporation Law provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation
and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys&rsquo;
fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person in connection with an action,
suit or proceeding to which he is or is threatened to be made a party by reason of such position, if such person acted in good
faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal
action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought
by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which
such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or
other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the
case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court
shall deem proper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As permitted by the Delaware General Corporation
Law, our certificate of incorporation and bylaws provide that: (i)&nbsp;we are required to indemnify our directors to the fullest
extent permitted by the Delaware General Corporation Law; (ii)&nbsp;we may, in our discretion, indemnify our employees and agents
as set forth in the Delaware General Corporation Law; (iii)&nbsp;we are required, upon satisfaction of certain conditions, to advance
all expenses incurred by our directors and officers in connection with certain legal proceedings; (iv)&nbsp;the rights conferred
in the bylaws are not exclusive; and (v)&nbsp;we are authorized to enter into indemnification agreements with our directors, officers,
employees and agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We maintain a directors&rsquo; and officers&rsquo;
liability insurance policy. The policy insures directors and officers against unindemnified losses arising from certain wrongful
acts in their capacities as directors and officers and reimburses us for those losses for which we have lawfully indemnified the
directors and officers. The policy contains various exclusions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the underwriting agreement, if any, entered
into with respect to an offering of securities registered hereunder, the underwriters will agree to indemnify, under certain conditions,
us, our directors, certain of our officers and persons who control us within the meaning of the Securities Act, against certain
liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 16. Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="text-align: center; padding-bottom: 1pt"> &nbsp; </td>
    <TD STYLE="text-align: center; padding-bottom: 1pt"> &nbsp; </td>
    <TD STYLE="text-align: center; padding-bottom: 1pt"> &nbsp; </td>
    <TD STYLE="text-align: center; padding-bottom: 1pt"> &nbsp; </td>
    <TD STYLE="text-align: center; padding-bottom: 1pt"> &nbsp; </td>
    <TD STYLE="text-align: center; padding-bottom: 1pt"> &nbsp; </td>
    <TD COLSPAN="5" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B> Incorporated
    by Reference </B></FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="width: 10%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B> Exhibit </B></FONT> <BR>
    <FONT STYLE="font-size: 10pt"><B>Number</B></FONT> </td>
    <TD NOWRAP STYLE="width: 1%; text-align: center; vertical-align: bottom; padding-bottom: 1pt"> &nbsp; </td>
    <TD NOWRAP STYLE="width: 42%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B> Description </B></FONT></td>
    <TD NOWRAP STYLE="width: 1%; text-align: center; vertical-align: bottom; padding-bottom: 1pt"> &nbsp; </td>
    <TD NOWRAP STYLE="width: 10%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B> Filed
    </B></FONT> <BR>
    <FONT STYLE="font-size: 10pt"><B>herewith</B></FONT> </td>
    <TD NOWRAP STYLE="width: 1%; text-align: center; vertical-align: bottom; padding-bottom: 1pt"> &nbsp; </td>
    <TD NOWRAP STYLE="width: 8%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B> Form </B></FONT></td>
    <TD NOWRAP STYLE="width: 1%; text-align: center; vertical-align: bottom; padding-bottom: 1pt"> &nbsp; </td>
    <TD NOWRAP STYLE="width: 15%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B> Filing
    date with SEC </B></FONT></td>
    <TD NOWRAP STYLE="width: 1%; text-align: center; vertical-align: bottom; padding-bottom: 1pt"> &nbsp; </td>
    <TD NOWRAP STYLE="width: 10%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B> Exhibit </B></FONT> <BR>
    <FONT STYLE="font-size: 10pt"><B>Number</B></FONT> </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right"> *1.1 </td>
    <TD> &nbsp; </td>
    <TD> Form of Underwriting Agreement </td>
    <TD> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD> &nbsp; </td>
    <TD> &nbsp; </td>
    <TD> &nbsp; </td>
    <TD> &nbsp; </td>
    <TD> &nbsp; </td>
    <TD> &nbsp; </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right"> 2.1 </td>
    <TD> &nbsp; </td>
    <TD> Agreement and Plan of Merger by and among Novelos Therapeutics, Inc., Cell Acquisition Corp. and Cellectar, Inc. dated
    April 8, 2011 </td>
    <TD> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> 8-K </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: center"> April 11, 2011 </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> 2.1 </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right"> 3.1 </td>
    <TD> &nbsp; </td>
    <TD> Second Amended and Restated Certificate of Incorporation </td>
    <TD> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> 8-K </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: center"> April 11, 2011 </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> 3.1 </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right"> 3.2 </td>
    <TD> &nbsp; </td>
    <TD> Certificate of Ownership and Merger of Cellectar Biosciences, Inc. with and into Novelos Therapeutics, Inc. </td>
    <TD> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> 8-K </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: center"> February 13, 2014 </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> 3.1 </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right"> 3.3 </td>
    <TD> &nbsp; </td>
    <TD> Certificate of Amendment to Second Amended and Restated Certificate of Incorporation </td>
    <TD> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> 8-K </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: center"> June 13, 2014 </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> 3.1 </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right"> 3.3 </td>
    <TD> &nbsp; </td>
    <TD> Amended and Restated By-Laws </td>
    <TD> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> 8-K </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: center"> June 1, 2011 </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> 3.1 </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right"> 4.1 </td>
    <TD> &nbsp; </td>
    <TD> Form of Common Stock Certificate </td>
    <TD> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> S-1/A </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: center"> November 9, 2011 </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> 4.1 </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right"> *4.2 </td>
    <TD> &nbsp; </td>
    <TD> Form of Warrant Agreement </td>
    <TD> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right"> *4.3 </td>
    <TD> &nbsp; </td>
    <TD> Form of Warrant </td>
    <TD> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right"> *4.4 </td>
    <TD> &nbsp; </td>
    <TD> Form of Unit Agreement </td>
    <TD> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right"> 5.1 </td>
    <TD> &nbsp; </td>
    <TD> Opinion of Foley Hoag LLP regarding the legality of securities being registered </td>
    <TD> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> S-3 </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: center"> January 9, 2015 </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> 5.1 </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right"> 23.1 </td>
    <TD> &nbsp; </td>
    <TD> Consent of Grant Thornton LLP </td>
    <TD> &nbsp; </td>
    <TD STYLE="text-align: center"> X </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"></td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: center"></td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right"> 23.2 </td>
    <TD> &nbsp; </td>
    <TD> Consent of Foley Hoag LLP (contained in Exhibit&nbsp;5.1) </td>
    <TD> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> S-3 </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: center"> January 9, 2015 </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> 23.2 </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right"> 24.1 </td>
    <TD> &nbsp; </td>
    <TD> Powers of Attorney (included on signature page) </td>
    <TD> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> S-3 </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: center"> January 9, 2015 </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> 24.1 </td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">*To be filed, if necessary,
by amendment or as an exhibit to a document incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 17. Undertakings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>The undersigned registrant hereby undertakes:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-indent: -13.5pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 13.5pt">1.</TD><TD>To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 22.5pt; text-align: left">(i)</TD><TD STYLE="text-align: justify">To include any prospectus required by Section 10(a)(3)
of the Securities Act of 1933;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 94.5pt; text-indent: -22.5pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 22.5pt">(ii)</TD><TD>To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most
recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information
set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered
(if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or
high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant
to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate
offering price set forth in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration statement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 94.5pt; text-indent: -22.5pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 22.5pt">(iii)</TD><TD STYLE="text-align: left">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement
or any material change to such information in the registration statement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>provided, however</I>, that paragraphs
(a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the information required to be included in a post-effective
amendment by those paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the
registrant pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration
statement, or is contained in a form of prospectus filed pursuant to Rule 424(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-indent: -13.5pt; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-indent: -13.5pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 13.5pt">2.</TD><TD>That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall
be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at
that time shall be deemed to be the initial bona fide offering thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-indent: -13.5pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 13.5pt">3.</TD><TD>To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold
at the termination of the offering.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-indent: -13.5pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 13.5pt">4.</TD><TD>That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 94.5pt; text-indent: -22.5pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 22.5pt">(i)</TD><TD>Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement
as of the date the filed prospectus was deemed part of and included in the registration statement; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 94.5pt; text-indent: -22.5pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 22.5pt">(ii)</TD><TD>Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance
on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information
required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement
as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale
of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any
person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement
relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration
statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by
reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with
a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement
or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-indent: -13.5pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 13.5pt">5.</TD><TD>That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial
distribution of the securities: The undersigned registrant undertakes that in a primary offering of securities of the undersigned
registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser,
if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant
will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 94.5pt; text-indent: -22.5pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 22.5pt">(i)</TD><TD>Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant
to Rule 424;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 94.5pt; text-indent: -22.5pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 22.5pt">(ii)</TD><TD>Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred
to by the undersigned registrant;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 94.5pt; text-indent: -22.5pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 22.5pt">(iii)</TD><TD>The portion of any other free writing prospectus relating to the offering containing material information about the undersigned
registrant or its securities provided by or on behalf of the undersigned registrant; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 94.5pt; text-indent: -22.5pt; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 72pt"></TD><TD STYLE="width: 22.5pt">(iv)</TD><TD>Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>That, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annual report
pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee
benefit plan's annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference
in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and
the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(c)</TD><TD>The undersigned registrant hereby undertakes to supplement the prospectus, after the expiration of the subscription period,
to set forth the results of the subscription offer, the transactions by the underwriters during the subscription period, the amount
of unsubscribed securities to be purchased by the underwriters, and the terms of any subsequent reoffering thereof. If any public
offering by the underwriters is to be made on terms differing from those set forth on the cover page of the prospectus, a post-effective
amendment will be filed to set forth the terms of such offering.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(d)</TD><TD>Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers
and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that
in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act
and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment
by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful
defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities
being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent,
submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed
in the Act and will be governed by the final adjudication of such issue.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Pursuant to the requirements of the
Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form S-3 and has duly caused this amendment to registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Madison, State of Wisconsin, on September 2, 2015. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD> &nbsp; </td>
    <td colspan="2"><B> CELLECTAR BIOSCIENCES, INC. </B></td>
    <TD> &nbsp; </td></tr>
<tr style="vertical-align: top">
    <TD> &nbsp; </td>
    <td colspan="2"> &nbsp; </td>
    <TD> &nbsp; </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"> &nbsp; </td>
    <TD STYLE="width: 5%; text-align: justify"> By: </td>
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid; text-align: justify"><I> /s/ James Caruso </I></td>
    <TD STYLE="width: 5%; text-align: justify"> &nbsp; </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify"> &nbsp; </td>
    <TD STYLE="text-align: justify"> &nbsp; </td>
    <TD STYLE="text-align: justify"> James Caruso </td>
    <TD STYLE="text-align: justify"> &nbsp; </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: justify"> &nbsp; </td>
    <TD STYLE="text-align: justify"> &nbsp; </td>
    <TD STYLE="text-align: justify"> President and Chief Executive Officer </td>
    <TD STYLE="text-align: justify"> &nbsp; </td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify; text-indent: -0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> Pursuant to the requirements of the
Securities Act of 1933, this amendment to the registration statement has been signed by a majority of the Board of Directors and
the following persons in the indicated capacities as of September 2, 2015. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td nowrap style="width: 30%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B> Signature </B></FONT></td>
    <td style="width: 5%"> &nbsp; </td>
    <td nowrap style="width: 65%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B> Title </B></FONT></td></tr>
<tr style="vertical-align: top">
    <td> &nbsp; </td>
    <td> &nbsp; </td>
    <td> &nbsp; </td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid"><I> /s/ James Caruso </I></td>
    <td> &nbsp; </td>
    <td> President, Chief Executive Officer and Director </td></tr>
<tr style="vertical-align: top">
    <td> James Caruso </td>
    <td> &nbsp; </td>
    <td><I> (Principal Executive Officer) </I></td></tr>
<tr style="vertical-align: top">
    <td> &nbsp; </td>
    <td> &nbsp; </td>
    <td> &nbsp; </td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid"><I> /s/ Chad J. Kolean </I></td>
    <td> &nbsp; </td>
    <td> Chief Financial Officer </td></tr>
<tr style="vertical-align: top">
    <td> Chad J. Kolean </td>
    <td> &nbsp; </td>
    <td><I> (Principal Financial Officer and Principal Accounting Officer) </I></td></tr>
<tr style="vertical-align: top">
    <td> &nbsp; </td>
    <td> &nbsp; </td>
    <td> &nbsp; </td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid"><I> ** /s/ Paul L. Berns </I></td>
    <td> &nbsp; </td>
    <td> Chairman of the Board of Directors&nbsp; </td></tr>
<tr style="vertical-align: top">
    <td> Paul L. Berns </td>
    <td> &nbsp; </td>
    <td> &nbsp; </td></tr>
<tr style="vertical-align: top">
    <td> &nbsp; </td>
    <td> &nbsp; </td>
    <td> &nbsp; </td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid"><I> ** /s/ Stephen A. Hill </I></td>
    <td> &nbsp; </td>
    <td> Director&nbsp; </td></tr>
<tr style="vertical-align: top">
    <td> Stephen A. Hill </td>
    <td> &nbsp; </td>
    <td> &nbsp; </td></tr>
<tr style="vertical-align: top">
    <td> &nbsp; </td>
    <td> &nbsp; </td>
    <td> &nbsp; </td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid"> &nbsp; </td>
    <td> &nbsp; </td>
    <td> Director&nbsp; </td></tr>
<tr style="vertical-align: top">
    <td> Stefan Loren </td>
    <td> &nbsp; </td>
    <td> &nbsp; </td></tr>
<tr style="vertical-align: top">
    <td> &nbsp; </td>
    <td> &nbsp; </td>
    <td> &nbsp; </td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid"><I> ** /s/ John Neis </I></td>
    <td> &nbsp; </td>
    <td> Director&nbsp; </td></tr>
<tr style="vertical-align: top">
    <td> John Neis </td>
    <td> &nbsp; </td>
    <td> &nbsp; </td></tr>
<tr style="vertical-align: top">
    <td> &nbsp; </td>
    <td> &nbsp; </td>
    <td> &nbsp; </td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid"><I> ** /s/ Jamey P. Weichert </I></td>
    <td> &nbsp; </td>
    <td> Director&nbsp; </td></tr>
<tr style="vertical-align: top">
    <td> Jamey P. Weichert </td>
    <td> &nbsp; </td>
    <td> &nbsp; </td></tr>
<tr style="vertical-align: top">
    <td> &nbsp; </td>
    <td> &nbsp; </td>
    <td> &nbsp; </td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> ** By Chad J. Kolean as attorney-in-fact </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font-size: 10pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>Exhibit Index</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="text-align: center; padding-bottom: 1pt"> &nbsp; </td>
    <TD STYLE="text-align: center; padding-bottom: 1pt"> &nbsp; </td>
    <TD STYLE="text-align: center; padding-bottom: 1pt"> &nbsp; </td>
    <TD STYLE="text-align: center; padding-bottom: 1pt"> &nbsp; </td>
    <TD STYLE="text-align: center; padding-bottom: 1pt"> &nbsp; </td>
    <TD STYLE="text-align: center; padding-bottom: 1pt"> &nbsp; </td>
    <TD COLSPAN="5" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B> Incorporated
    by Reference </B></FONT></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="width: 10%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B> Exhibit </B></FONT> <BR>
    <FONT STYLE="font-size: 10pt"><B>Number</B></FONT> </td>
    <TD NOWRAP STYLE="width: 1%; text-align: center; vertical-align: bottom; padding-bottom: 1pt"> &nbsp; </td>
    <TD NOWRAP STYLE="width: 42%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B> Description </B></FONT></td>
    <TD NOWRAP STYLE="width: 1%; text-align: center; vertical-align: bottom; padding-bottom: 1pt"> &nbsp; </td>
    <TD NOWRAP STYLE="width: 10%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B> Filed
    </B></FONT> <BR>
    <FONT STYLE="font-size: 10pt"><B>herewith</B></FONT> </td>
    <TD NOWRAP STYLE="width: 1%; text-align: center; vertical-align: bottom; padding-bottom: 1pt"> &nbsp; </td>
    <TD NOWRAP STYLE="width: 8%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B> Form </B></FONT></td>
    <TD NOWRAP STYLE="width: 1%; text-align: center; vertical-align: bottom; padding-bottom: 1pt"> &nbsp; </td>
    <TD NOWRAP STYLE="width: 15%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B> Filing
    date with SEC </B></FONT></td>
    <TD NOWRAP STYLE="width: 1%; text-align: center; vertical-align: bottom; padding-bottom: 1pt"> &nbsp; </td>
    <TD NOWRAP STYLE="width: 10%; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B> Exhibit </B></FONT> <BR>
    <FONT STYLE="font-size: 10pt"><B>Number</B></FONT> </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right"> *1.1 </td>
    <TD> &nbsp; </td>
    <TD> Form of Underwriting Agreement </td>
    <TD> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD> &nbsp; </td>
    <TD> &nbsp; </td>
    <TD> &nbsp; </td>
    <TD> &nbsp; </td>
    <TD> &nbsp; </td>
    <TD> &nbsp; </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right"> 2.1 </td>
    <TD> &nbsp; </td>
    <TD> Agreement and Plan of Merger by and among Novelos Therapeutics, Inc., Cell Acquisition Corp. and Cellectar, Inc. dated
    April 8, 2011 </td>
    <TD> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> 8-K </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: center"> April 11, 2011 </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> 2.1 </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right"> 3.1 </td>
    <TD> &nbsp; </td>
    <TD> Second Amended and Restated Certificate of Incorporation </td>
    <TD> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> 8-K </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: center"> April 11, 2011 </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> 3.1 </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right"> 3.2 </td>
    <TD> &nbsp; </td>
    <TD> Certificate of Ownership and Merger of Cellectar Biosciences, Inc. with and into Novelos Therapeutics, Inc. </td>
    <TD> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> 8-K </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: center"> February 13, 2014 </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> 3.1 </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right"> 3.3 </td>
    <TD> &nbsp; </td>
    <TD> Certificate of Amendment to Second Amended and Restated Certificate of Incorporation </td>
    <TD> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> 8-K </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: center"> June 13, 2014 </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> 3.1 </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right"> 3.3 </td>
    <TD> &nbsp; </td>
    <TD> Amended and Restated By-Laws </td>
    <TD> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> 8-K </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: center"> June 1, 2011 </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> 3.1 </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right"> 4.1 </td>
    <TD> &nbsp; </td>
    <TD> Form of Common Stock Certificate </td>
    <TD> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> S-1/A </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: center"> November 9, 2011 </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> 4.1 </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right"> *4.2 </td>
    <TD> &nbsp; </td>
    <TD> Form of Warrant Agreement </td>
    <TD> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right"> *4.3 </td>
    <TD> &nbsp; </td>
    <TD> Form of Warrant </td>
    <TD> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right"> *4.4 </td>
    <TD> &nbsp; </td>
    <TD> Form of Unit Agreement </td>
    <TD> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right"> 5.1 </td>
    <TD> &nbsp; </td>
    <TD> Opinion of Foley Hoag LLP regarding the legality of securities being registered </td>
    <TD> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> S-3 </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: center"> January 9, 2015 </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> 5.1 </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right"> 23.1 </td>
    <TD> &nbsp; </td>
    <TD> Consent of Grant Thornton LLP </td>
    <TD> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp;X </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"></td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: center"></td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right"> 23.2 </td>
    <TD> &nbsp; </td>
    <TD> Consent of Foley Hoag LLP (contained in Exhibit&nbsp;5.1) </td>
    <TD> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> S-3 </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: center"> January 9, 2015 </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> 23.2 </td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: right"> 24.1 </td>
    <TD> &nbsp; </td>
    <TD> Powers of Attorney (included on signature page) </td>
    <TD> &nbsp; </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> S-3 </td>
    <TD STYLE="text-align: center"> &nbsp; </td>
    <TD STYLE="text-align: center"> January 9, 2015 </td>
    <TD STYLE="text-align: right"> &nbsp; </td>
    <TD STYLE="text-align: right"> 24.1 </td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">*To be filed, if necessary,
by amendment or as an exhibit to a document incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>v419548_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Consent of Independent Registered Public Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have issued our report dated March&nbsp;24, 2015 (except
for the effects of the restatement described in Note A1, as to which the date is May 20, 2015), with respect to the consolidated
financial statements included in the Annual Report on Form 10-K/A for the year ended December&nbsp;31, 2014 of Cellectar Biosciences,
Inc., which is incorporated by reference in this Registration Statement. We consent to the incorporation by reference in the Registration
Statement of the aforementioned report, and to the use of our name as it appears under the caption &ldquo;Experts.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ GRANT THORNTON LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Appleton, Wisconsin</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">September 2, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tlogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlogo.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ =P&^ P$1  (1 0,1 ?_$ -4  0 !! (# 0
M       )!@<("@(% P0+ 0$!   ' 0$               $" P0%!@<("1
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M%:K47]R3]H$EI&1G]-<$WI(N*;J.XC(.0CEL5:0DE2@*3I+6,>Y)Z<>V*8!
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M1>G*47\Y-OK^M*3DLX 57#E2YSF&W0H  >#]WW_<.47LNZ;I(Z2>0TJ36@Z
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M+@4.9JLU]P9&YT%K&(1U]#LD$"2#:'0.L@95I')*I*J*/G@ 8@++KG2^T<0
M3CUKTGS[=_\ ZPX?&WBML7O!HT 5^/Q69O))K"S+K<5IT6";[?>Z\H,=%'*Y
MJRH]GR\"S(T#U+@4Q0^0;F<6$P] [K_77E+<?=3W3WNU=<V4UW"^1U71M8ZC
M.[!:ZS<=SNHVDM-2.@4+7N0<).;O*7,,2<ZLUAM+/FPH$!XO(2;B*Q]H=8JH
M*G<GR628,&]AMU !'SM;K7TO_LPYW9;#L4\O/9I)9I)VN#I006CTZ$"N.)5W
M;6^X/!,K3JKU\%C;J[]G,YWYB**V=R>G=11ZWIG5&3RQQELL4IOYPIF&*,%V
MP+)_K%,YM7K^_P#[D>%;9-(RSMWSV#7U;1N&L99T5R[;;B<:7CRYYK81]KCV
M?8OV\,LS;9LUMY7:>?YIC+3$2IQV.#B^,0$,600E'Q6K=60D7\H]>.FQ !54
MR94R%Z$N(C7G[W-]W;WW,D8TQ^A91NJT=2!E7 #Y$K+6UI]L ,RIL*Y.KQ>,
M1M>]_/P^CZ_IJVDF;"ZD;"Z1QZ!3C%6?V'R"T9J4##M#;NM]?'*%Q;Y=F6/P
MCP0 .X3$9/I!)VH %ZB)2" >=9*':]\NXQ/:P2F(]0QS@?B 0I'-97STK\E;
M?$^<7#G.'Q8S%.3FCYE^=3TDVK?8V-)+**=  B0.I! %3"(] +>_E59VP\CB
MQDM9BVE<(W9?)&B,?32OBLGFCYF_00=L'"+UFY*51L[:*I.FCA,UA*J@Y1.=
M%1,P#T,41 :QDC/3DT31ELH/48@]_9\5'4O>JHH)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$6)'.W
M9RNFN&O)C9;=44'N,Z:SI2,6*?TSI2\E"N(:'4(?Q*=.3D4C (=;A6P\)VP;
MWS;:;%^-O)=-#QV@.!(^0*EE=2!Q.>D_O7S!2=YB]RI_45/\:BEQ$QU#@!CF
M.(B(B<QA$1'S&OJ%;ZXFF/(,<6#N:W!H^ ^*U!O[U76L\"D=I[)U]K.)*8TE
ML#-<8PYD4H"(@MD4PSB_5"P]UT$G)C] 'H4:QO(-Q=LW'[W=8W:'1PXGY]JF
M:QKYF!PJ*KZG6L=>X]JK7F"ZVQ=DDPQ[ L4@<3A6J1"D*DP@HQ".1Z$ "]ZA
M4>\XAXG,(^=?+B_O)]PW*XW"X<72SR%Q)[R2MO;1C=#<&JO:M45@=];@)JK&
M"J,NQSDLP8[6$:JV,DB8"E%Q(NB!\9D&8&"Q ^V>P>%QKEWN?SJTXGM$D8>&
MW[F^7N5G>W8MH-0_ZG11.S\_-9-).):?DW<M(.3F.LY>*F4,(F^T1,EQ312\
M@(3X0#I7S]W?D>Z\EE?=[G/)(7N.9I@,!]-.@6C2S33R&69Q=(>JZ;I:WETZ
M?DM;ZZQ+&"%GK1.>)F'RG4[#\53J:UZK(K2&]9S7$PSBY5ZYD,)=."HO&2Z@
MK'B15[2!(1YA,82(HB8!.F%@$ 'SKMOMI[OW^PWT-ON\[Y+$G06NI3S>4=*X
M$K+;?N5Q#,UKWDQ=F"EA:G1=-T7*!RJHN$DUDE$[ 11-8A3D4)V^1RC?\E>[
MK8QRPQW-L0+25@=I %#J%:X8]5N0=6,.9F>JXR43&3+-6/EF#228K  *M'J"
M;ENI;P[DE2F((A^2IKS;[*_A%O>1-DA'1PP1P#VECL6E>O'8] Q"148N'C(Y
M(H !2,F3=L  '@'\BF0:HVNS;39-++6VA8TFIHQN/S"E9''& (V@4[EV@))E
MO8MK_6/TW^GZ:OA%$!1K0!2F I^5%5+W',K\*BD0"@4@ !;]H!?I?J-NOG4(
MH8H&&.(4836F>/QJFMRY=A0 0 +=1'S\?&_Z:3,#V8YC$>(R4*FJ_#' HE 1
M"YAL #YV +VJE-*^/TVMQ<XXJ- H'.3G+'DKRZY*Y-P.X"SZ>"L, _D>27)H
M4@<(X,0R@-GV-8BNG]B5;',*1E$3"Z7= 9)(R1$U%*[/QSC^S<4V=O.N:1MG
ML7?]*V<2-9(U-.!:< *XF@ZU5+U"YQ8S,*\^G_95X680D2:VIBF0<D]B//Z3
MD&>[IR29R%S*R)NXSAPC"IOD8]LBJJ>X H"YS!]HPC>L+<>Z?(+B4S;)*VSV
MQ^,<3&1EK&DX %S"3@I76['FLU7/^7Y*]V9>U%[>68QJK"0XI:Q:=Z0HD>XX
MP>8S*-P$!LJW?PSUFLFL0>H'&X@(7JA%[G<Y@+G#<'Z2#4&.(U^;/R4HMHAB
MP4/BL))3@YRXX$9-%;$]O#8>7[?U.I.QC?.N(FW<K+),UX=VZ*D^>X#E4XX1
M;Q#ADF<#=QA26(4!,)ER@)*N[?E_&N6;?-!O=M''NVDEMPRK3KS\PR\W7 @C
M 4*JB+0ZN/@5.I O)-_$1KZ8C#PDF\8,W,A"J.F[\\0]7;)JNHTS]I=J].R7
M,9(54_Y-02=Q>@US:=ACN"8W:H?S[^WO50@#!8(>X'SJ'@A@>N\U-JJ8W ZV
M/L9GK>)QF$R%GCC\DI(L';QBJDX=1,L5X=RNV*W(B4A3&44 >[RK;N"\)O>:
M;A?Q"Y9;6UM ) 7"H ICU%/B:89*4D-S"Q!_M5N7A1,4WM'<H;E,)?\ K(RO
MT&W7_ KQ :VV+VTV!L3?5Y-MP>6XAU*_&CP%2?.UKJ%I0?=7Y=^7M'<H/SY(
MS'^#"PJXB]LN.2&G^J-K%.W_ /=2?<M_E*RDXD<V=\<BMDR>$[,X+[FXT03#
M&7,\WSC84LW?PTE((NV;9* ;))0$48CUPDX.J4?4-\*0]*U3E'$=IV*$3V.]
MV=])K ].+,UK4_4<!F5,R=KW::4*DBK2566"?"3FNQYF$WTLPU_(X &C-SSV
MGG1'\^SGPR1S"()K&GVIFD='_=S=P!K W/ZAB^9QO6Q\MXM>\5NXK>ZDJ^2(
M24 PH<E1M7NDBU/SJ5G64;A?\O\ "-:V"'"HR55M:8K]J*BNKFY$(B%EY8R9
ME2Q<8_D3)$,!#*E8M570I%.(& @J E8!L-KU,V(S/;$TD%S@*CO*+#_@;S%8
M\Y-%'W=&X&_UPW+G6683^'9&=:Y$Y%3%5FJ"DB,@TCXU$$WPN>XJ?IW3 +"8
M?&LSR;8+KCE\W;KEW^>6-=V8.K_@I032JS4K"*9*(J7S.?/BN+Y)DX-S.R8W
MCTU/J,B*%1.\+#1SB2,T*L<ARHF<E:B0#B4P$$UQ ?"C+:XO;JWLK=VE\UPQ
MA/8":)6B@DUK[T^]MPXHUSG5GMB<@-@X<]>2,<SR;%LSCI.'<O8AP+21;)NT
M<+%,R[-P'8H ?9-TKL]_[2;?M=_)9[GO]E;S-:TZ7BGU"H_752/D:UNJAHJ^
M_M5^77_ZCN4/^4C+_P!RZM/_ *VXY_\ Z?;/V_XU2^Y;V%>S'^Z;RX>R$>S7
M]IGDVQ0>/F;-9\MD3(4&23EPFBJ\7 <-)=-LF<3B%PN!1ZA5K>^WW'+6V<\<
MFVUTE,*9_P#G3[IO\I4V;-8[AHU752,BHNW1641,("9$ZB93F2,(  "9,QNT
M1\Q"N6!H8- >) ,-7\W?\<U<5!Q&2M[MG;.O-(X//[*VIF,/@V#8PQ%[,9!-
MNDVS5N%S BW1*)3K/7SPX=B+=(IUECV*0HC5UMUC?[KN+-MVZ)TUU(/*T DU
MQ[/"I[E(Z01YCHH@&GNI\CN0S]W_ -PO@ML#<6"-G2S5'<.TY9OK+"9<R1S)
M"O#(/P;*.F_J%$;_ #0G[?M$*/2NC6_ -EVJ#[KF&[MM;D/HZV8S7* 0344.
M PZM.:D$WJ"D;3J[>B[)QS!]WC K2VQ/;APW,L<1 7+]'4.W6,CDB+,OQG(V
MCW+V34</"H@/0J)RB:IY>.>VE^!;;;ODT-P\@:I8?**X5R;2G;6G:%$&5GFD
M%6CL65G$?W'=&<LYJ5P".+E.I]X8XB)\GT7MB*_#6>QHH";YQ:-1<E20R!DV
M_7.W %"%^(Q  0&M;Y#P/>>,1-OG/%WL;G4;<-^EPZ$Z<&UZ ]F:@+AKLADL
MC^2>W,TTAIO)=E8!I[*M\Y5!J0Y([6.%N2-<CR$LC*LV#I1@N=C(E*6.:N#N
M%/Y(UTTQZAXUK>RVT>\7C;:>5MM"]Q_S'9 #$'&F?BK@4./<HM/[57E^%P'V
MC^3]^[P_$;/P\K#^#!#\]=2B]L^/!A,O)]N:[36CACX8/5&29L;M.DY*WT?[
MV6ZY?9&0:=BO;,WR_P!JXI#L\AR;7S?.8M?*8."?D:J,Y:1BR86"S9BY*^1$
MAQZ&!4OTUD1[/;5'M#-WDY-MOVTDA8TD=0*T^L#+HJ7W3#^DU5PC^ZKR_ AA
M#VCN3]^TPA_A(R"]@N%A'#+!?Z1\*Q<?MKQZ6L7^I]NUG*E*_#STJIV3M>X-
MTE3 ZFS&=V!K;!\XR;#I;74_EN+P^02^ SZI%YO#7\FS3=.<?E5TT&Q57\8H
MH*2A@3( F*/PA7*=PMX]NW63;8)Q<L8ZFL4H0.HHKBE<0K@',(!?N&_@%K=1
M&]@ !"PB/EU\:M7/?'""<9":?BAHH3>3WO5:RXX\D)S1:6I,NV-C6OY+#(G<
M.V\;G6;;&]:2.6/RM%F4A'GAWIWJL,DL0R@&=-Q45 Z1/B+UZMM'M7N^Z;!'
MR 3,8R?4(XW?4=&%1E35\:9JFYP!HIH8*9CLABHZ;AWS>3B9B/92L7(M%"JM
M7T?(-R.F3MNH01*=%RV5(<H@(@(&KE[XY;:X?:35]5AQKVU((^!"FH1FNV'Z
MJ@\.+:--'(L+N>?,!IP=X_2>_'^"R&R&L7E6*XP;%HV<:8XZ<*92_,P2=$E'
MD=)H$*T. ")!1$3WL @-;%PWCMQS7?V;!8/].=U3J(J,!4U[J*E,YS!J&2P$
M:>Z_RU?M6SUE[2O)ITT>-D'C5PADS(Z+AJZ2*NV<)'##! Z2Z)RF*/F A6^3
M^VG'X)=#N3;9@:?MYU)]RW^4KV/[57EZ'4?:-Y0" >/;DC*]O.U\,M>U#[:\
M=KAR?:]/[?[Z?<M_E*[/!O>:QMKLO%M8\J^,>[^'4CF\@E%8IDVR6I)/"GT@
MZ4(DT;/ILD3#G9@JJJ4IE2I*)HB8!4$I/BJSW+VLE=9.N^.;I;;EZ(K(V"E6
MC/(EU2:8#"O:H"XU. &"FG^92^6^9]='TOEP<>OZB?H>D*0J>MZU_3]'L#N[
MK]MNM[5RT5=*8176TT.&-3ADKFAIWJ*KWN7[B.]LCDR9L82BZA\2CU1 1*(M
MGN=8VBX)T\CIF$!^H:Z7[,Z(_<&P+\1#(7>-!AX9JC=.T0E?.Q"U@L !8 #I
MX=.GZ>E?2&0ZI'24IK<74[*XT6K%NDT4@?M3PK2?]QKA^Q>@D9!'<,/* 140
M[#KPS&1EFP"!@$#C\PS+8OF-JYM[O7<MO[:;K'$,9(0-5<6T/3QR5>UC]2X;
MCD5]*8GZO[O(1_37S6A!]"/4?,/XK:7&E O+5PH**_E_).7>UDF"IC>A%8Y&
M$;$Z@0!>F6<KF*6]A,93H(^-@M7@[^X:\FO.=C:IG&.R9$':AC4TRIDM3Y#(
M[UPT?2L5QKA!<QQK&-+,@/##\<U@B:FJ_* T\%!?I>A@&U^H>72P#<P#] &+
M</JO4DY@HQSAH#9&.J.T.!'S*@:FE#3$*8_CY)NI73^$.7:BBJQ(KY,55#"8
MZA6#A9HF<3#U'N31"OI)[7[A<;CQ*WNYB2T,#0/"G4KHED*6C*XFBO371U76
M+_+_ )4X7PST/F'(+84)D.0XGACO'6<C%XHDS6G5SY).1\"T,U2D73%H<J3J
M0*8]U0^ !MU"U93CVT77)MX9LFVT-X]U!7 5S_)2R.$;-94,?_\ 3)PX\]0<
M@/S1.&C_ .U85W)G]M'N$X5<;1O_ (I"*^'E5@-RAR=@?V[E?7C/[\W&+E)O
M776@L(UGN6&RK94PM#1$IDD=B[>#9KMXYY)**R"S'(GKHB0H,C '8D81,(!6
M Y5[&\NX?LLN_;L^U-E$0#H>7.J<J"@^?158KR*9XCCQ<5.$"G<41L'01 ;#
M?SMXV"N)-<YT;C(--"1_%7KQHIXA6VW'D[K"M3;.S-D03/<1U[FV2,B@4QQ%
MY"8W(R+4 *7J;^7;%J^VN(W.]65AI!BFE:TFM* N -/$*8^4:E$=["F"QL=P
ME';2MGF;[UVEL'-LXGE[+24LZ8S+B&CT7CD1]02MBME52E&_QKG-XFKH'O+>
M.N.3V^Q@F.PM(&1AF8<0W$]VJ@KGE165FTESY#U>5-T0.@_4-O"WD%<N$8<X
MAHT,9Y0!E3/]ZO"ZI*\@A?\ =>J],*=/S4*KCV?7_P"2 5+Z3&M(A 83U"CJ
M7*U QU*.-2H54!_OU23&&UMPXF)1V@PBXGF-KR5DG[D1(V81T:BY>/WKE3M-
MZ2#1J@=0YQ"Q2E$:[9[(VMS<_P"H+=M'2NV\Z16E<#0>-51G?Z9:!U4A7]I/
MP',)K\M=)@(',7X<U9"'PF$/(UKA:N>MX'S%U7"PE(J<@#AXU_@JCGQL-'''
M-51A7/#AOLG+8# ]?\DM4Y?F64OPC8#&H/*VKR7EWHI*+_*L&A!$ZZWI(F-8
M/(HC5EN'$.4;;#]U=VKX;9OU.<T9=RBQ\;\&XE9;%3N8AP,;H-Q _7R$.E["
M UKA ?,"UK26G$TQ'@IL*9+V:NE*H&O8X^%I[@/^VSGW7P\&3;I^_75_>1LD
MFY;5*]Y+KK:XY3_NYC2.T85J:*VL,8?^(J>,OA^G^$:Y.,AX*NW+XG\URJ*F
M5,9MUPS+O^S$_P#]%.ZJP.+)V/&8>#\BBAI]@3_Z"S__ #ZV^/Y?Z?%!72O>
MR(GEMG<:CCMT4A'2IU"GP5*%^L.;3JIO:Y@JJ416WW#TU1LX;V_S=YO^?_!B
M4_15WM)IR#;JN+6F\CPI@?,,RH'!I=V!0$^S)S0XIZ5X*X3@&VM^ZSU[F++.
M]HOW>-Y+DB$9+-F<EECIW'.%6BA2&(D\;* <@CT, ]*['[L\+Y5?\YGNMOM'
M36)CC\S3JJ?3:!AX@UKET4D3FF'U78 &BE7'W)N P (CRVTH   B(CFK( "W
MF(]W0*YN[@7,6M+C82@ ?RC_ !4WJQ=JRTPO,<6V/BT#FV$SS#)L/RB,;3&.
MY'$.BNXR:C'A>]L^CW!0$JS18O4IPZ"%:E<VYM93!>!HG!H6Z>O8JM!V*K@N
M1,   ,)2ATZ!>W[P4)='"#&T5%!IZ!2T'P6NYRM@W/N!>ZS@/##+'KT_'#C-
M@K'<.T<6:.5466;94]19OV$=, DH +D [YBU ! !30.Y[1 R@#7<>-W#.&^W
MTW*[8 ;_ '%P8XW]61Z0*C_BU./P5%SQZXA+006UJM@K'\;@\6BHV!QN*CX*
M"AV"$;$0L2S;Q\7%L&I")H-&+)H1)NV02(4  I0 *XK/+<7\[K^]D=-=R.)+
MW8DUQQJJM6AU  "NY,D!P$!$0 P6&PB'B%N@WZ51="U[2UU-)&. 4:K'[+^*
MF@<\V]@V^\LUICTKN'7!%R8CGP(N&,['@L42!\PXCW#4)0$"B/I Z!8$@,8"
MV PA6;BW[>X=M=LK;F3^CN-?2.+1X5K2O6G7%0(8<2T560G: %[0$0Z %PZ#
MT_)T"L06C2&-P RHB\!R_$ =QAOTN)A\[_1:K.;5'I:#74\-J17.O^"BVCB0
M>@4%.CK_ -O9S0+<>G&#5HW ;"-XG7MBB/\ P0OT#Z:[9N\,4?LWM+VM9ZDF
MZ3$NTC5@U[:5ZC"JHA[73EFD5#<U.P0G0H]QNH /C]5ZXPV(EQ-0/ 4_%5L.
MQ>0"6OUO?Z0O^X*J>BUH)C\LAZYE1JL)_< Y:PW#7C'L'<#L47&4ILAQK6D&
M8UU\@V%/)+M,>9D0 !.LW9+ 9VX H=$$!\!$*V?A7'+KD_)(]ME ;MK!K?)F
M0T8NJ,A7(8XU4I.%5@CP:]MJ(><"-EXIR+8FEMO\U6$CL'<<])I^I.0\I/F7
MF<';%66!19%]B3IT1^8HC\+U54/ *V_F7.IX.86O]$H-DVYS8](<0VC0!(X
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MI1Q Q8#TSS5*&,>EZ<G4U4J@^V=P L-N'^A[V&W^ L3X^7@6]<X/N!S*A_\
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M/>IX9ZK7TYJ?6O%F3Q'\99/EZ+K+\V%_+B^R1TDJZ**[-VP2!M9N04RBGW%
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M:R:9F,DR.3=S60Y#*R,Y.S#]4R[V5EY5VL^D9%VL<1.JY>.ES*'$;")C> >
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M+P'F7%G:=VLI&,)P< 2#\1^^BS3;B)W4+/TIP4 #E,(E,%RB!A[1#Z0$ $!
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M=@4JZ^065;LW*Z0B)T6SA8OA:Z2)CE[K^/4OA;K]5&.$KXVC NI@ILS10O\
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MGQJ+8&*XGN?%<0Y$:XRJ23B#[+U*P#&,FPQ=7JF_RO&9!PBS5B"!<3J(C<
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MRX66GB,#Q4VH(?KJRD.>/=KJ6#[1S&-]=;!MW*>1[?!]K!<.CM^P$.'_ ##
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&*(E$7__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
